John Clarke

VISICU, Inc. provides information technology and clinical solutions for healthcare industry. It offers eICU program, a remote monitoring system for intensive care units. The company was founded by Brian Rosenfeld and Michael J. Breslow in 1998 and is headquartered in Baltimore, MD.

Momenta Pharmaceuticals, Inc. operates as a biotechnology company that focuses on the discovery and development of novel biologic therapies for the treatment of rare immune-mediated diseases. Its products include the Glatiramer acetate injection and Enoxaparin Sodium injection. The company was founded by Ram Sasisekharan, Paul R. Schimmel, and Ganesh Venkatraman Kaundinya in May 2001 and is headquartered in Cambridge, MA.

Sirtris Pharmaceuticals, Inc., a GSK company, is developing small molecule drugs that target the sirtuins, a family of seven enzymes associated with diseases of aging. Modulation of these enzymes offers the promise of drug discovery in multiple therapeutic areas. Sirtris was one of the pharmaceutical companies focused on the sirtuin platform and remains the innovative drug discovery. Preclinical research indicates that the sirtuins play important roles in pathways for multiple diseases of aging, including Type 2 Diabetes, as well as neurodegenerative, cardiovascular and inflammatory diseases. Sirtris researchers are working to translate this research into a potential new class of pharmaceuticals to treat diseases of aging, offering the ability for people to live longer, healthier lives. Sirtris has focused on developing many novel small molecule activators of SIRT1, the most studied member of the sirtuin family. These new chemical entities or NCEs are novel compounds that are chemically unrelated to resveratrol, a naturally occurring compound that was used as an early proof-of-concept for SIRT1 activation. Besides being structurally differentiated from resveratrol, the NCEs are more specific for the target SIRT1 and have improved drug-like properties. The company has completed several early stage translational clinical studies with the first generation NCEs and has several active clinical trials under way. Sirtris operates as an independent Discovery Performance Unit (DPU) within GSK and is located in Technology Square, Cambridge, Mass. Sirtris' culture mixes scientific curiosity with a dynamic, fast-paced environment, resembling its biotech roots while harnessing all of GSK's broad discovery, development, and commercialization capabilities. The company was founded in 2004 and is headquartered in Cambridge, MA.

Ivenix, Inc. operates as a medical device company. It develops and supplies infusion systems and intravenous-infusion pumps that eliminate air in the fluid bag line. The company was founded by John L. Bakos and Jeffrey Carlisle in 2007 and is headquartered in Amesbury, MA.

Cureatr, Inc. engages in the provision of comprehensive medication management solutions. Its solutions include meds 360, medication management, care transitions, secure messaging, and meds 360 for population. The company was founded by Joseph Mayer and Alex Khomenko in October 2011 and is headquartered in New York, NY.

Abide Therapeutics, Inc. develops medicines that target serine hydrolases. Its approach is to selectively block serine hydrolases, potentially expanding this class of commercially validated enzymes as targets in a range of indications. The firm has a technology platform that exploits a chemoproteomics approach to selectively target serine hydrolases and rapidly identify target lead pairs. The company was founded by Alan B. Ezekowitz, Dale Boger, John Kennedy Clarke, Benjamin F. Cravatt, Todd Jones, Keith F. Lenden, and Paul R. Schimmel in 2011 and is headquartered in San Diego, CA.

CHP Management Inc (Cardinal Partners) is a venture capital firm founded in 1996 by John K Clarke, Brandon H Hull and John J Park. The firm is headquartered in Princeton, New Jersey.

TechRx, Inc. used to provide software solutions to retailers. The company was founded in 1992 by Timothy R. Burns and was headquartered in Warminister, PA.

Melinta Subsidiary Corp. develops and markets pharmaceutical products for the treatment of life-threatening infections. It also develops novel classes of antibiotics to treat the multi- and extremely-drug-resistant pathogens for which there are few to no options, known collectively as ESKAPE pathogens. The company was founded by John N. Abelson, Harry F. Noller, Susan Froshauer, Harry H. Penner, Jr., William L. Jorgensen, Thomas A. Steitz, and Peter Moore in October 2000 and is headquartered in New Haven, CT.

The Jackson Laboratory provides biotechnology research services. It offers nonprofit research, biomedical research, genomics, genetics, cancer, neuroscience, immunology, aging, bioinformatics, computational biology, research mice, genomic medicine, reproductive biology, developmental biology, eye research and hearing research. The company was founded by Clarence Cook Little in 1929 and is headquartered in Bar Harbor, ME.

National Venture Capital Association provides business association services. It facilitates networking opportunities and provides research data to its members. The company is headquartered in Washington, DC.

Philadelphia Industrial Development Corp. engages in the provision of leverage financing and real estate resources. It offers business loans, project development finance, tax advantaged financing, grants administration and additional resources, and real estate which include navy yard, industrial land and city owned property. The company was founded in 1958 and is headquartered in Philadelphia, PA.

Vividion Therapeutics, Inc. operates as a biotechnology company. The company focuses on developing innovative therapeutics that treat major unmet clinical needs using the first platform for proteome wide drug and target discovery. It's proprietary chemoproteomic platform technology addresses the key limitations of conventional screening techniques and allows the discovery of previously unknown, or cryptic, functional pockets on the surface of proteins and identification of small molecules that selectively bind to those targets. The company was founded by Benjamin F. Cravatt, Phil S. Baran, Jin-Quan Yu and John K. Clarke on December 24, 2013 and is headquartered in San Diego, CA.

Prealize Health, Inc. engages in the development of machine learning solutions for improving healthcare focusing on predicting impending medical conditions. It specializes in data sciences and healthcare. The company was founded by Arnold Milstein and Nigam Shah in 2013 and is headquartered in Palo Alto, CA.